Geron-logo-black-xsmall.png
Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates
May 21, 2020 16:01 ET | Geron Corporation
Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival (OS) as a primary endpoint, which is expected to open for screening and enrollment in...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
May 14, 2020 16:05 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Geron-logo-black-xsmall.png
Geron to Present at Needham Virtual Healthcare Conference
April 08, 2020 16:30 ET | Geron Corporation
MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Geron-logo-black-xsmall.png
Geron Provides COVID-19 Related Business Update
April 02, 2020 08:00 ET | Geron Corporation
MENLO PARK, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced an update to information from...
Aprea logo 445pt.png
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 26, 2020 08:00 ET | Aprea Therapeutics
BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results
March 24, 2020 16:05 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial Results
March 18, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Geron-logo-black-xsmall.png
Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones
March 12, 2020 16:05 ET | Geron Corporation
MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat,...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Participation in Two Upcoming International Conferences
February 18, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York City
February 04, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...